Latest news with #Ixchiq
New York Post
16-05-2025
- Health
- New York Post
Seniors should avoid this vaccine after deadly complications discovered, FDA says
Older adults are being warned against receiving the chikungunya vaccine before traveling. The Ixchiq vaccination, developed by Valneva to prevent the mosquito-borne chikungunya virus, was approved by the Food and Drug Administration (FDA) in November 2023 as the first of its kind. The approval applies to anyone aged 18 and older who has a risk of being exposed to the virus. But the FDA and the Centers for Disease Control and Prevention (CDC) released a safety notice on May 9 recommending that adults over 60 years old pause use of the vaccine due to fatal complications. 'FDA and CDC will continue the evaluation of post-marketing safety reports for Ixchiq,' the release reads. 'While the safety of Ixchiq for use in individuals 60 years of age and older is being further assessed, FDA and CDC are recommending a pause in use of the vaccine in this age group. FDA and CDC will update the public when the agencies complete their evaluation of this safety issue.' 3 The FDA is advising seniors to avoid getting the chikungunya vaccine before traveling. InsideCreativeHouse – The advisory follows reports of 'serious adverse events,' including neurologic and cardiac events in people who received the vaccine. Two of 17 events resulted in death from severe complications. One death was caused by encephalitis, or inflammation in the brain, the alert stated. 3 The Ixchiq vaccination was developed to prevent the mosquito-borne chikungunya virus. wirakorn – Those who experienced adverse effects of the vaccine were reported to be between the ages of 62 and 89. The FDA warned that Ixchiq, which contains a live, weakened version of chikungunya, may cause symptoms similar to the virus. Typical symptoms of chikungunya include fever, severe joint pain, headache, muscle pain and a rash, according to the CDC. Most people recover within a week, but some may experience 'severe and disabling' joint pain for weeks or months. 3 A patient infected with chikungunya looks out from mosquito netting at the Clinicas Hospital in San Lorenzo, Paraguay, in 2023. AP 'This virus is in a similar category as dengue or Zika and is carried by the same mosquitoes,' Fox News senior medical analyst Dr. Marc Siegel previously told Fox News Digital. At the time of the vaccine's approval, the FDA described chikungunya as an 'emerging global health threat,' with at least five million cases reported over the past 15 years. The FDA plans to conduct an 'updated benefit-risk assessment' for Ixchiq use in those over 60 years of age, according to the notice.
Yahoo
13-05-2025
- Health
- Yahoo
FDA warns seniors to avoid this vaccine after deadly complications
Older adults are being warned against receiving the chikungunya vaccine before traveling. The Ixchiq vaccination, developed by Valneva to prevent the mosquito-borne chikungunya virus, was approved by the Food and Drug Administration (FDA) in November 2023 as the first of its kind. The approval applies to anyone aged 18 and older who has a risk of being exposed to the virus. First Vaccine For Chikungunya Virus, An 'Emerging Global Health Threat,' Gets Fda Approval But the FDA and the Centers for Disease Control and Prevention (CDC) released a safety notice on May 9 recommending that adults over 60 years old pause use of the vaccine due to fatal complications. "FDA and CDC will continue the evaluation of post-marketing safety reports for Ixchiq," the release reads. Read On The Fox News App "While the safety of Ixchiq for use in individuals 60 years of age and older is being further assessed, FDA and CDC are recommending a pause in use of the vaccine in this age group. FDA and CDC will update the public when the agencies complete their evaluation of this safety issue." The advisory follows reports of "serious adverse events," including neurologic and cardiac events in people who received the vaccine. Two of 17 events resulted in death from severe complications. One death was caused by encephalitis, or inflammation in the brain, the alert stated. Those who experienced adverse effects of the vaccine were reported to be between the ages of 62 and 89. The FDA warned that Ixchiq, which contains a live, weakened version of chikungunya, may cause symptoms similar to the virus. Typical symptoms of chikungunya include fever, severe joint pain, headache, muscle pain and a rash, according to the CDC. Click Here To Sign Up For Our Health Newsletter Most people recover within a week, but some may experience "severe and disabling" joint pain for weeks or months. "This virus is in a similar category as dengue or Zika and is carried by the same mosquitoes," Fox News senior medical analyst Dr. Marc Siegel previously told Fox News Digital. At the time of the vaccine's approval, the FDA described chikungunya as an "emerging global health threat," with at least five million cases reported over the past 15 years. For more Health articles, visit The FDA plans to conduct an "updated benefit-risk assessment" for Ixchiq use in those over 60 years of age, according to the notice. Fox News Digital's Melissa Rudy contributed to this article source: FDA warns seniors to avoid this vaccine after deadly complications
Fox News
13-05-2025
- Health
- Fox News
FDA warns seniors to avoid this vaccine after deadly complications
Older adults are being warned against receiving the chikungunya vaccine before traveling. The Ixchiq vaccination, developed by Valneva to prevent the mosquito-borne chikungunya virus, was approved by the Food and Drug Administration (FDA) in November 2023 as the first of its kind. The approval applies to anyone aged 18 and older who has a risk of being exposed to the virus. But the FDA and the Centers for Disease Control and Prevention (CDC) released a safety notice on May 9 recommending that adults over 60 years old pause use of the vaccine due to fatal complications. "FDA and CDC will continue the evaluation of post-marketing safety reports for Ixchiq," the release reads. "While the safety of Ixchiq for use in individuals 60 years of age and older is being further assessed, FDA and CDC are recommending a pause in use of the vaccine in this age group. FDA and CDC will update the public when the agencies complete their evaluation of this safety issue." The advisory follows reports of "serious adverse events," including neurologic and cardiac events in people who received the vaccine. Two of 17 events resulted in death from severe complications. One death was caused by encephalitis, or inflammation in the brain, the alert stated. Those who experienced adverse effects of the vaccine were reported to be between the ages of 62 and 89. The FDA warned that Ixchiq, which contains a live, weakened version of chikungunya, may cause symptoms similar to the virus. Typical symptoms of chikungunya include fever, severe joint pain, headache, muscle pain and a rash, according to the CDC. Most people recover within a week, but some may experience "severe and disabling" joint pain for weeks or months. "This virus is in a similar category as dengue or Zika and is carried by the same mosquitoes," Fox News senior medical analyst Dr. Marc Siegel previously told Fox News Digital. At the time of the vaccine's approval, the FDA described chikungunya as an "emerging global health threat," with at least five million cases reported over the past 15 years. For more Health articles, visit The FDA plans to conduct an "updated benefit-risk assessment" for Ixchiq use in those over 60 years of age, according to the notice.
Global News
13-05-2025
- Health
- Global News
Older adults in U.S. urged to skip this travel vaccine. What about Canada?
The United States is advising travellers aged 60 and up to hold off on getting the chikungunya vaccine while it looks into reports of possible side effects, including heart problems, neurological issues and even death. The Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) posted a notice on May 9 about the complications from the vaccine, which is sold under the name Ixchiq from manufacturer Valneva. 'As of May 7, 2025, 17 serious adverse events, including two that resulted in death, have been reported in individuals 62 through 89 years of age who received Ixchiq during postmarketing use globally,' the notice warned. Health Canada, for its part, said it is monitoring the safety of Ixchiq and will take 'appropriate action' if new information emerges that could change the vaccine's benefit-risk profile. Story continues below advertisement The agency has not issued any warning against its use in older adults. What is chikungunya? Chikungunya is a virus spread to people through mosquito bites. It's mostly found in parts of the Americas, Asia, and Africa, with the occasional outbreak in Europe. Get weekly health news Receive the latest medical news and health information delivered to you every Sunday. Sign up for weekly health newsletter Sign Up By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy The illness causes symptoms similar to dengue and Zika — most notably a high fever and severe joint pain that can be long-lasting. Other symptoms include swelling, muscle aches, headache, nausea, fatigue and a rash. 2:19 Health Matters: Health Canada approves chikungunya vaccine About 100 to 200 cases are reported annually among U.S. travellers. Story continues below advertisement The latest data from the Public Health Agency of Canada shows that as of Dec. 9, 2014, 320 confirmed and 159 probable cases of chikungunya have been identified in Canada among travellers returning from affected areas in both the Americas and the Asia-Pacific region. The vaccine is available in both Canada and the U.S. for travellers heading to countries where the risk of catching chikungunya is higher. The shot contains a live, weakened version of the chikungunya virus and may cause symptoms similar to those of chikungunya disease. But last month, a panel of vaccine experts who advise the CDC heard about an investigation into six people 65 and older — most of them with other medical problems — who became ill with heart or brain symptoms less than a week after vaccination. One person died from encephalitis. More than 10 other similar cases have been reported in people from other countries. The U.S. advisers then voted to issue a precaution for people 65 and older about getting the vaccine. European regulators are also looking into the issue and restricting its use. 'Given that studies on Ixchiq mainly involved people below 65 years of age and the vast majority of serious cases concerned people 65 years of age and above, the Committee is temporarily recommending restricting the use of vaccine,' a statement by the European Medicines Agency said on May 7. Story continues below advertisement 0:55 Here's how hard Zika virus hit Canadian tourists last year — With files from The Associated Press
Indianapolis Star
13-05-2025
- Health
- Indianapolis Star
Feds recommend pausing vaccine for mosquito-borne disease chikungunya in people over 60
Federal drug safety officials have recommended pausing the use of a vaccine for a mosquito-borne disease known as chikungunya for people over 60 following reports of serious adverse events. The U.S. Food and Drug Administration said that 17 serious adverse events, including two that resulted in death, have been reported in worldwide recipients of the vaccine Ixchiq over the age of 60. Six of the events occurred in the United States, the FDA said in a safety communication on Monday, May 12. Domestic and global cases have been reported to the Vaccine Adverse Event Reporting System, run by the FDA and the U.S. Centers for Disease Control to flag potential safety problems with vaccines. The reported cases were in individuals with underlying chronic medical conditions and the adverse events "may not be causally related to vaccination," the FDA said. The vaccine's maker, Valneva, said in a statement that it is "upholding the highest safety standards" and pointed to the potential for underlying conditions and other medications as contributing factors in the adverse events. "Thorough evaluation of these cases is critical to ensure the safe use of Ixchiq," the company said. French drug regulators updated their recommendations for Ixchiq in April and the European Medicines Agency announced that its safety committee had launched a review of the vaccine earlier this month and prohibited its use in people 65 and older, according to the Center for Infectious Disease Research and Policy at the University of Minnesota. Chikungunya is a mosquito-borne illness named for the joint pain it causes, according to the Cleveland Clinic. Most people infected by a mosquito bite recover from the illness in about one week, but some have lasting joint pain – the clinic says. There is no cure for the disease and treatment focuses on managing symptoms inlcuding: The FDA approved Ixchiq for the prevention of the disease in adults over 18 in November 2023. It uses a live, though weakened, version of the virus that may cause symptoms similar to the disease, according to the FDA. The FDA said that some of the reported adverse events were consistent with severe complications of chikungunya disease.
